[1]
|
Wong, V.W., Chan, W.K., Chitturi, S., Chawla, Y., Dan, Y.Y., Duseja, A., et al. (2018) Asia-Pacific Working Party on Non-Alcoholic Fatty Liver Disease Guidelines 2017-Part 1: Definition, Risk Factors and Assessment. Journal of Gastroenterology and Hepatology, 33, 70-85. https://doi.org/10.1111/jgh.13857
|
[2]
|
Tilg, H., Moschen, A.R. and Roden, M. (2017) NAFLD and Diabetes Mellitus. Nature Reviews Gastroenterology & Hepatology, 14, 32-42. https://doi.org/10.1038/nrgastro.2016.147
|
[3]
|
Armstrong, M.J., Adams, L.A., Canbay, A. and Syn, W.-K. (2014) Extrahepatic Complications of Nonalcoholic Fatty Liver Disease. Hepatology, 59, 1174-1197. https://doi.org/10.1002/hep.26717
|
[4]
|
Foretz, M., Guigas, B., Bertrand, L., Pollak, M. and Viollet, B. (2014) Metformin: From Mechanisms of Action to Therapies. Cell Metabolism, 20, 953-966. https://doi.org/10.1016/j.cmet.2014.09.018
|
[5]
|
Flory, J. and Lipska, K. (2019) Metformin in 2019. JAMA, 321, 1926-1927. https://doi.org/10.1001/jama.2019.3805
|
[6]
|
Viollet, B., Guigas, B., Sanz, G.N., Leclerc, J., Foretz, M. and Andreelli, F. (2012) Cellular and Molecular Mechanisms of Metformin: An Overview. Clinical Science, 122, 253-270. https://doi.org/10.1042/CS20110386
|
[7]
|
Evans, T.D., Zhang, X., Jeong, S.J., He, A., Song, E., Bhattacharya, S., et al. (2019) TFEB Drives PGC-1α Expression in Adipocytes to Protect against Diet-Induced Metabolic Dysfunction. Science Signaling, 12, Article No. eaau2281.
https://doi.org/10.1126/scisignal.aau2281
|
[8]
|
Zhang, D., Ma, Y., Liu, J., Deng, Y., Zhou, B., Wen, Y., et al. (2021) Metformin Alleviates Hepatic Steatosis and Insulin Resistance in a Mouse Model of High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease by Promoting Transcription Factor EB-Dependent Autophagy. Frontiers in Pharmacology, 12, Article No. 689111.
https://doi.org/10.3389/fphar.2021.689111
|
[9]
|
王玉莹, 刘蕴玲. 二甲双胍治疗非酒精性脂肪性肝病的研究进展[J]. 临床内科杂志, 2021, 38(5): 355-357.
|
[10]
|
Soccio, R.E., Chen, E.R. and Lazar, M.A. (2014) Thiazolidinediones and the Promise of Insulin Sensitization in Type 2 Diabetes. Cell Metabolism, 20, 573-591. https://doi.org/10.1016/j.cmet.2014.08.005
|
[11]
|
Belfort, R., Harrison, S.A., Brown, K., Darland, C., Finch, J., Hardies, J., et al. (2006) A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis. New England Journal of Medicine, 355, 2297-2307.
https://doi.org/10.1056/NEJMoa060326
|
[12]
|
Aithal, G.P., Thomas, J.A., Kaye, P.V., Lawson, A., Ryder, S.D., Spendlove, I., et al. (2008) Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects with Nonalcoholic Steatohepatitis. Gastroenterology, 135, 1176-1184. https://doi.org/10.1053/j.gastro.2008.06.047
|
[13]
|
Lewis, J.D., Habel, L.A., Quesenberry, C.P., Strom, B.L., Peng, T., Hedderson, M.M., et al. (2015) Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons with Diabetes. JAMA, 314, 265-277.
https://doi.org/10.1001/jama.2015.7996
|
[14]
|
Yau, H., Rivera, K., Lomonaco, R. and Cusi, K. (2013) The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus. Current Diabetes Reports, 13, 329-341. https://doi.org/10.1007/s11892-013-0378-8
|
[15]
|
Andersen, A., Lund, A., Knop, F.K. and Vilsbøll, T. (2018) Glucagon-Like Peptide 1 in Health and Disease. Nature Reviews Endocrinology, 14, 390-403. https://doi.org/10.1038/s41574-018-0016-2
|
[16]
|
Armstrong, M.J., Hull, D., Guo, K., Barton, D., Hazlehurst, J.M., Gathercole, L.L., et al. (2016) Glucagon-Like Peptide 1 Decreases Lipotoxicity in Non-Alcoholic Steatohepatitis. Journal of Hepatology, 64, 399-408.
https://doi.org/10.1016/j.jhep.2015.08.038
|
[17]
|
Seghieri, M., Rebelos, E., Gastaldelli, A., Astiarraga, B.D., Casolaro, A., Barsotti, E., et al. (2013) Direct Effect of GLP-1 Infusion on Endogenous Glucose Production in Humans. Diabetologia, 56, 156-161.
https://doi.org/10.1007/s00125-012-2738-3
|
[18]
|
Xiao, C., Dash, S., Morgantini, C., Adeli, K. and Lewis, G.F. (2015) Gut Peptides Are Novel Regulators of Intestinal Lipoprotein Secretion: Experimental and Pharmacological Manipulation of Lipoprotein Metabolism. Diabetes, 64, 2310-2318. https://doi.org/10.2337/db14-1706
|
[19]
|
Armstrong, M.J., Gaunt, P., Aithal, G.P., et al. (2016) Liraglutide Safety and Efficacy in Patients with Non-Alcoholic Steatohepatitis (LEAN): A Multicentre, Double-Blind, Randomised, Placebo-Controlled Phase 2 Study. Lancet, 387, 679-690. https://doi.org/10.1016/S0140-6736(15)00803-X
|
[20]
|
Yakaryilmaz, F., Guliter, S., Savas, B., Erdem, O., Ersoy, R., Erden, E., et al. (2007) Effects of Vitamin E Treatment on Peroxisome Proliferator-Activated Receptor-Alpha Expression and Insulin Resistance in Patients with Non-Alcoholic Steatohepatitis: Results of a Pilot Study. Internal Medicine Journal, 37, 229-235.
https://doi.org/10.1111/j.1445-5994.2006.01295.x
|
[21]
|
Abner, E.L., Schmitt, F.A., Mendiondo, M.S., Marcum, J.L. and Kryscio, R.J. (2011) Vitamin E and All-Cause Mortality: A Meta-Analysis. Current Aging Science, 4, 158-170. https://doi.org/10.2174/1874609811104020158
|
[22]
|
Klein, E.A., Thompson, I.J., Tangen, C.M., Crowley, J.J., Lucia, M.S., Goodman, P.J., et al. (2011) Vitamin E and the Risk of Prostate Cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA, 306, 1549-1556.
https://doi.org/10.1001/jama.2011.1437
|
[23]
|
Dufour, J.F., Oneta, C.M., Gonvers, J.J., Bihl, F., Cerny, A., Cereda, J.M., et al. (2006) Randomized Placebo-Controlled Trial of Ursodeoxycholic Acid with Vitamin E in Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology, 4, 1537-1543. https://doi.org/10.1016/j.cgh.2006.09.025
|
[24]
|
Leuschner, U.F., Lindenthal, B., Herrmann, G., Arnold, J.C., Rössle, M., Cordes, H.-J., et al. (2010) High-Dose Ursodeoxycholic Acid Therapy for Nonalcoholic Steatohepatitis: A Double-Blind, Randomized, Placebo-Controlled Trial. Hepatology, 52, 472-479. https://doi.org/10.1002/hep.23727
|
[25]
|
Lindor, K.D., Kowdley, K.V., Heathcote, E.J., Harrison, M.E., Jorgensen, R., Angulo, P., et al. (2004) Ursodeoxycholic Acid for Treatment of Nonalcoholic Steatohepatitis: Results of a Randomized Trial. Hepatology, 39, 770-778.
https://doi.org/10.1002/hep.20092
|
[26]
|
Masterton, G.S., Plevris, J.N. and Hayes, P.C. (2010) Review Article: Omega-3 Fatty Acids—A Promising Novel Therapy for Non-Alcoholic Fatty Liver Disease. Alimentary Pharmacology & Therapeutics, 31, 679-692.
https://doi.org/10.1111/j.1365-2036.2009.04230.x
|
[27]
|
Sanyal, A.J., Abdelmalek, M.F., Suzuki, A., Cummings, O.W. and Chojkier, M. (2014) No Significant Effects of Ethyl-Eicosapentanoic Acid on Histologic Features of Nonalcoholic Steatohepatitis in a Phase 2 Trial. Gastroenterology, 147, 377-384.E1. https://doi.org/10.1053/j.gastro.2014.04.046
|
[28]
|
Balabanov, S., Braig, M., Brummendorf, T.H. (2014) Current Aspects in Resistance against Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia. Drug Discovery Today: Technologies, 11, 89-99.
https://doi.org/10.1016/j.ddtec.2014.03.003
|
[29]
|
Wolf, A.M., Wolf, D., Rumpold, H., Ludwiczek, S., Enrich, B., Gastl, G., et al. (2005) The Kinase Inhibitor Imatinib Mesylate Inhibits TNF-α Production in Vitro and Prevents TNF-Dependent Acute Hepatic Inflammation. Proceedings of the National Academy of Sciences of the United States of America, 102, 13622-13627.
https://doi.org/10.1073/pnas.0501758102
|
[30]
|
Al Asfoor, S., Rohm, T.V., Bosch, A., Dervos, T., Calabrese, D., Matter, M.S., et al. (2018) Imatinib Reduces Non-Alcoholic Fatty Liver Disease in Obese Mice by Targeting Inflammatory and Lipogenic Pathways in Macrophages and Liver. Scientific Reports, 8, Article No. 15331. https://doi.org/10.1038/s41598-018-32853-w
|
[31]
|
Chawla, A. (2010) Control of Macrophage Activation and Function by PPARs. Circulation Research, 106, 1559-1569.
https://doi.org/10.1161/CIRCRESAHA.110.216523
|
[32]
|
Souza-Mello, V. (2015) Peroxisome Proliferator-Activated Receptors as Targets to Treat Non-Alcoholic Fatty Liver Disease. World Journal of Hepatology, 7, 1012-1019. https://doi.org/10.4254/wjh.v7.i8.1012
|
[33]
|
Chan, S.M., Sun, R.Q., Zeng, X.Y., Choong, Z.H., Wang, H., Watt, M.J., et al. (2013) Activation of PPARalpha Ameliorates Hepatic Insulin Resistance and Steatosis in High Fructose-Fed Mice Despite Increased Endoplasmic Reticulum Stress. Diabetes, 62, 2095-2105. https://doi.org/10.2337/db12-1397
|
[34]
|
Magliano, D.C., Bargut, T.C., de Carvalho, S.N., Aguila, M.B., Mandarim-de-Lacerda, C.A., Souza-Mello, V., et al. (2013) Peroxisome Proliferator-Activated Receptors-Alpha and Gamma Are Targets to Treat Offspring from Maternal Diet-Induced Obesity in Mice. PLoS ONE, 8, Article ID: e64258. https://doi.org/10.1371/journal.pone.0064258
|
[35]
|
Federico, A., Dallio, M., Caprio, G.G., Ormando, V.M. and Loguercio, C. (2017) Gut Microbiota and the Liver. Minerva Gastroenterologica e Dietologica, 63, 385-398. https://doi.org/10.23736/S1121-421X.17.02375-3
|
[36]
|
Kobyliak, N., Conte, C., Cammarota, G., Haley, A.P., Styriak, I., Gaspar, L., et al. (2016) Probiotics in Prevention and Treatment of Obesity: A Critical View. Nutrition & Metabolism, 13, Article No. 14.
https://doi.org/10.1186/s12986-016-0067-0
|
[37]
|
Kobyliak, N., Abenavoli, L., Falalyeyeva, T., Mykhalchyshyn, G., Boccuto, L., Kononenko, L., et al. (2018) Beneficial Effects of Probiotic Combination with Omega-3 Fatty Acids in NAFLD: A Randomized Clinical Study. Minerva Medica, 109, 418-428. https://doi.org/10.23736/S0026-4806.18.05845-7
|
[38]
|
王薇, 史林平, 石蕾, 等. 肠道益生菌辅助治疗非酒精性脂肪性肝病的临床研究[J]. 中华内科杂志, 2018, 57(2): 101-106.
|
[39]
|
Brooks, S.R., Brooks, J.S., Lee, W.H., Lee, M.G. and Kim, S.G. (2009) Therapeutic Potential of Dithiolethiones for Hepatic Diseases. Pharmacology & Therapeutics, 124, 31-43. https://doi.org/10.1016/j.pharmthera.2009.06.006
|
[40]
|
Kim, W., Kim, B.G., Lee, J.S., Lee, C.K., Yeon, J.E., Chang, M.S., et al. (2017) Randomised Clinical Trial: The Efficacy and Safety of Oltipraz, a Liver X Receptor Alpha-Inhibitory Dithiolethione in Patients with Non-Alcoholic Fatty Liver Disease. Alimentary Pharmacology & Therapeuticsr, 45, 1073-1083. https://doi.org/10.1111/apt.13981
|
[41]
|
Konikoff, F.M. and Gilat, T. (2005) Effects of Fatty Acid Bile Acid Conjugates (FABACs) on Biliary Lithogenesis: Potential Consequences for Non-Surgical Treatment of Gallstones. Current Drug Targets—Immune, Endocrine & Metabolic Disorders, 5, 171-175. https://doi.org/10.2174/1568008054064904
|
[42]
|
Dobrzyn, A. and Ntambi, J.M. (2005) Stearoyl-CoA Desaturase as a New Drug Target for Obesity Treatment. Obesity Reviews, 6, 169-174. https://doi.org/10.1111/j.1467-789X.2005.00177.x
|
[43]
|
Safadi, R., Konikoff, F.M., Mahamid, M., Zelber-Sagi, S., Halpern, M., Gilat, T., et al. (2014) The Fatty Acid-Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients with Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 12, 2085-2091.E1. https://doi.org/10.1016/j.cgh.2014.04.038
|
[44]
|
Lancaster, L., Morrison, L., Auais, A., Ding, B., Iqbal, A., Polman, B., et al. (2017) Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis: Experience from 92 Sites in an Open-Label US Expanded Access Program. Pulmonary Therapy, 3, 317-325. https://doi.org/10.1007/s41030-017-0049-z
|
[45]
|
Garcia, L., Hernandez, I., Sandoval, A., Salazar, A., Garcia, J., Vera, J., et al. (2002) Pirfenidone Effectively Reverses Experimental Liver Fibrosis. Journal of Hepatology, 37, 797-805. https://doi.org/10.1016/S0168-8278(02)00272-6
|
[46]
|
Tsuchiya, H., Kaibori, M., Yanagida, H., Yokoigawa, N., Kwon, A.H., Okumura, T., et al. (2004) Pirfenidone Prevents Endotoxin-Induced Liver Injury after Partial Hepatectomy in Rats. Journal of Hepatology, 40, 94-101.
https://doi.org/10.1016/j.jhep.2003.09.023
|
[47]
|
Wang, F., Wen, T., Chen, X.Y. and Wu, H. (2008) Protective Effects of Pirfenidone on D-Galactosamine and Lipopolysaccharide-Induced Acute Hepatotoxicity in Rats. Inflammation Research, 57, 183-188.
https://doi.org/10.1007/s00011-007-7153-8
|
[48]
|
Chen, G., Ni, Y., Nagata, N., Xu, L., Zhuge, F., Nagashimada, M., et al. (2019) Pirfenidone Prevents and Reverses Hepatic Insulin Resistance and Steatohepatitis by Polarizing M2 Macrophages. Laboratory Investigation, 99, 1335-1348.
https://doi.org/10.1038/s41374-019-0255-4
|
[49]
|
Volkmann, X., Fischer, U., Bahr, M.J., Ott, M., Lehner, F., MacFarlane, M., et al. (2007) Increased Hepatotoxicity of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Diseased Human Liver. Hepatology, 46, 1498-1508.
https://doi.org/10.1002/hep.21846
|
[50]
|
Farrell, G.C., Larter, C.Z., Hou, J.Y., Zhang, R.H., Yeh, M.M., Williams, J., et al. (2009) Apoptosis in Experimental NASH Is Associated with p53 Activation and TRAIL Receptor Expression. Journal of Gastroenterology and Hepatology, 24, 443-452. https://doi.org/10.1111/j.1440-1746.2009.05785.x
|
[51]
|
Barreyro, F.J., Holod, S., Finocchietto, P.V., Camino, A.M., Aquino, J.B., Avagnina, A., et al. (2015) The Pan-Caspase Inhibitor Emricasan (IDN-6556) Decreases Liver Injury and Fibrosis in a Murine Model of Non-Alcoholic Steatohepatitis. Liver International, 35, 953-966. https://doi.org/10.1111/liv.12570
|
[52]
|
Staels, B., Handelsman, Y. and Fonseca, V. (2010) Bile Acid Sequestrants for Lipid and Glucose Control. Current Diabetes Reports, 10, 70-77. https://doi.org/10.1007/s11892-009-0087-5
|
[53]
|
Braunlin, W., Zhorov, E., Guo, A., Apruzzese, W., Xu, Q., Hook, P., et al. (2002) Bile Acid Binding to Sevelamer HCl. Kidney International, 62, 611-619. https://doi.org/10.1046/j.1523-1755.2002.00459.x
|
[54]
|
Harach, T., Pols, T.W., Nomura, M., Maida, A., Watanabe, M., Auwerx, J., et al. (2012) TGR5 Potentiates GLP-1 Secretion in Response to Anionic Exchange Resins. Scientific Reports, 2, Article No. 430.
https://doi.org/10.1038/srep00430
|
[55]
|
Kobayashi, M., Ikegami, H., Fujisawa, T., Nojima, K., Kawabata, Y., Noso, S., et al. (2007) Prevention and Treatment of Obesity, Insulin Resistance, and Diabetes by Bile Acid-Binding Resin. Diabetes, 56, 239-247.
https://doi.org/10.2337/db06-0353
|